Abstract
Imiquimod (AldaraTM), a Toll-like receptor 7 agonist (TLR7), is known for its unique properties of being an immune response modifier and stimulator. Upon topical application, this TLR7 agonist triggers a cell-mediated immune response predominantly expressed by dendritic cells and monocytes. Local skin irritation at the application site involving erythema, pain, crusting and erosions is common and well documented. On the contrary, the specific histopathologic features associated with these treatment site reactions is not. Herein reported is a case where historical omission of imiquimod use for actinic keratosis complicated the histologic interpretation. We highlight a lupus erythematosus-like microscopic pattern and explore histopathologic features that could help in avoiding a diagnostic pitfall, as well as the relationship between TLR activation, cell-mediated immunity and skin histology.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 346-350 |
| Number of pages | 5 |
| Journal | Journal of Cutaneous Pathology |
| Volume | 38 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2011 |
Fingerprint
ASJC Scopus subject areas
- Dermatology
- Pathology and Forensic Medicine
- Histology
Cite this
Lupus erythematosus-like imiquimod reaction : A diagnostic pitfall. / Barr, Keira L.; Konia, Thomas; Fung, Maxwell A.
In: Journal of Cutaneous Pathology, Vol. 38, No. 4, 04.2011, p. 346-350.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Lupus erythematosus-like imiquimod reaction
T2 - A diagnostic pitfall
AU - Barr, Keira L.
AU - Konia, Thomas
AU - Fung, Maxwell A
PY - 2011/4
Y1 - 2011/4
N2 - Imiquimod (AldaraTM), a Toll-like receptor 7 agonist (TLR7), is known for its unique properties of being an immune response modifier and stimulator. Upon topical application, this TLR7 agonist triggers a cell-mediated immune response predominantly expressed by dendritic cells and monocytes. Local skin irritation at the application site involving erythema, pain, crusting and erosions is common and well documented. On the contrary, the specific histopathologic features associated with these treatment site reactions is not. Herein reported is a case where historical omission of imiquimod use for actinic keratosis complicated the histologic interpretation. We highlight a lupus erythematosus-like microscopic pattern and explore histopathologic features that could help in avoiding a diagnostic pitfall, as well as the relationship between TLR activation, cell-mediated immunity and skin histology.
AB - Imiquimod (AldaraTM), a Toll-like receptor 7 agonist (TLR7), is known for its unique properties of being an immune response modifier and stimulator. Upon topical application, this TLR7 agonist triggers a cell-mediated immune response predominantly expressed by dendritic cells and monocytes. Local skin irritation at the application site involving erythema, pain, crusting and erosions is common and well documented. On the contrary, the specific histopathologic features associated with these treatment site reactions is not. Herein reported is a case where historical omission of imiquimod use for actinic keratosis complicated the histologic interpretation. We highlight a lupus erythematosus-like microscopic pattern and explore histopathologic features that could help in avoiding a diagnostic pitfall, as well as the relationship between TLR activation, cell-mediated immunity and skin histology.
UR - http://www.scopus.com/inward/record.url?scp=79951732489&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79951732489&partnerID=8YFLogxK
U2 - 10.1111/j.1600-0560.2010.01592.x
DO - 10.1111/j.1600-0560.2010.01592.x
M3 - Article
VL - 38
SP - 346
EP - 350
JO - Journal of Cutaneous Pathology
JF - Journal of Cutaneous Pathology
SN - 0303-6987
IS - 4
ER -